836 related articles for article (PubMed ID: 33686237)
1. Beyond immune checkpoint blockade: emerging immunological strategies.
Kubli SP; Berger T; Araujo DV; Siu LL; Mak TW
Nat Rev Drug Discov; 2021 Dec; 20(12):899-919. PubMed ID: 33686237
[TBL] [Abstract][Full Text] [Related]
2. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.
Pan C; Liu H; Robins E; Song W; Liu D; Li Z; Zheng L
J Hematol Oncol; 2020 Apr; 13(1):29. PubMed ID: 32245497
[TBL] [Abstract][Full Text] [Related]
3. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
4. Turning tumors from cold to inflamed to improve immunotherapy response.
Gerard CL; Delyon J; Wicky A; Homicsko K; Cuendet MA; Michielin O
Cancer Treat Rev; 2021 Dec; 101():102227. PubMed ID: 34656019
[TBL] [Abstract][Full Text] [Related]
5. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
6. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
Bader JE; Voss K; Rathmell JC
Mol Cell; 2020 Jun; 78(6):1019-1033. PubMed ID: 32559423
[TBL] [Abstract][Full Text] [Related]
7. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
8. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C; Liu Y
Front Immunol; 2020; 11():1295. PubMed ID: 32714324
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
10. Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies.
Ajina R; Zahavi DJ; Zhang YW; Weiner LM
Semin Cancer Biol; 2020 Oct; 65():28-37. PubMed ID: 31866479
[TBL] [Abstract][Full Text] [Related]
11. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
Dzobo K
OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
[TBL] [Abstract][Full Text] [Related]
12. It takes two to tango: the role of tumor-associated macrophages in T cell-directed immune checkpoint blockade therapy.
Sheban F
Front Immunol; 2023; 14():1183578. PubMed ID: 37359522
[TBL] [Abstract][Full Text] [Related]
13. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
14. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
15. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Fukumura D; Kloepper J; Amoozgar Z; Duda DG; Jain RK
Nat Rev Clin Oncol; 2018 May; 15(5):325-340. PubMed ID: 29508855
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity.
Donlon NE; Power R; Hayes C; Reynolds JV; Lysaght J
Cancer Lett; 2021 Apr; 502():84-96. PubMed ID: 33450360
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
[TBL] [Abstract][Full Text] [Related]
18. Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response.
Francis A; Venkatesh GH; Zaarour RF; Zeinelabdin NA; Nawafleh HH; Prasad P; Buart S; Terry S; Chouaib S
Crit Rev Immunol; 2018; 38(6):505-524. PubMed ID: 31002604
[TBL] [Abstract][Full Text] [Related]
19. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
[TBL] [Abstract][Full Text] [Related]
20. Big opportunities for small molecules in immuno-oncology.
Adams JL; Smothers J; Srinivasan R; Hoos A
Nat Rev Drug Discov; 2015 Sep; 14(9):603-22. PubMed ID: 26228631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
